Retention Rate of Acalabrutinib in a Non-interventional Setting

Study acronym: RETAIN
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Oct 15, 2026 → Apr 15, 2027
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 15, 2026 to Apr 15, 2027 Show 4 more changesShow less
    • Enrollment increased: 137 → 193 participants
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 7 of 15 entries
    • Site details revised at 2 of 61 sites
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 137
    • Study sites: 62 to 61
    v33
  3. 2 versions Re-verified since Jul 25, 2025, no change to tracked fieldsv31-v32
  4. Site details revised at 1 of 62 sitesv30
  5. Site details revised at 7 of 62 sitesv29
Show 27 earlier versionsHide 27 earlier versions
  1. Site details revised at 7 of 62 sitesv28
  2. Study sites: 61 to 62v27
  3. Site details revised at 3 of 61 sitesv26
  4. Study sites: 55 to 61v25
  5. Site details revised at 8 of 55 sitesv24
  6. Primary and study completion dates: Apr 15, 2026 to Oct 15, 2026v23
  7. Study sites: 54 to 55v22
  8. 2 versions Re-verified since Jul 18, 2024, no change to tracked fieldsv20-v21
  9. Study sites: 53 to 54v19
  10. Study sites: 51 to 53v18
  11. Study sites: 50 to 51v17
  12. Study sites: 46 to 50v16
  13. Study sites: 38 to 46v15
  14. Study sites: 36 to 38v14
  15. Re-verified, no change to tracked fieldsv13
  16. Study sites: 35 to 36v12
  17. Study sites: 31 to 35v11
  18. Site details revised at 29 of 31 sitesv10
  19. Study sites: 28 to 31v9
  20. Study sites: 16 to 28v8
  21. Study sites: 8 to 16v7
  22. Re-verified, no change to tracked fieldsv6
  23. Study sites: 5 to 8v5
  24. Study sites: 2 to 5v4
  25. Study sites: 1 to 2v3
  26. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 15, 2022 to Dec 12, 2022
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.
Trial Details
NCT Number NCT05645172
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Chronic Lymphocytic Leukaemia (CLL)
Related terms Leukemia, B-Cell
Enrollment 193 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov